All PlansCoverageMedium impact
Gene Expression Profiling for Cutaneous Melanoma
Blue Cross & Blue Shield of Mississippi·MS · Dermatology, Oncology, Pathology·Medical Policy
Effective date
Oct 1, 2025
We identified it
Jun 20, 2026
Summary
This policy update declares all gene expression profiling tests for melanoma evaluation as investigational and non-covered, including specific tests like Pigmented Lesion Assay, myPath Melanoma, and DecisionDx-Melanoma. A new CPT code 0578U was added effective 10/01/2025 for a melanoma gene expression test, but it remains investigational.
Action Required
Immediately: Billing team must verify that all melanoma gene expression profiling tests (CPT codes 0089U, 0090U, 0314U, 0387U, 0578U, 81479, 81529, 81599, 84999) are flagged as investigational/non-covered in billing system. Update prior authorization systems to deny these codes automatically. Notify providers that these tests are not covered and will result in claim denials or patient financial responsibility.